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Abstract
Objective
Determine the decay rate of HIV-1 DNA reservoir in vertically infected children during sus-
tained viral suppression (VS) and how it is affected by the age at VS.
Methods
This study included 37 HIV-1 vertically infected children on suppressive antiretroviral ther-
apy for at least 4 years. Children were grouped according to the age of antiretroviral therapy
initiation (�0.5 or >0.5 yrs) and to the age at VS (�1.5, between >1.5 and 4, and >4 years).
Decay of cell-associated HIV-1 DNA (CA-HIV-DNA) level and 2-long terminal repeats (2-
LTR) circles frequency were analyzed over 4 years of viral suppression using piecewise lin-
ear mixed-effects model with two splines and logistic regression, respectively.
Results
CA-HIV-DNA in peripheral blood mononuclear cells had a significant decay during the first
two years of VS [-0.26 (95% CI: -0.43, -0.09) log10 copies per one million cells (cpm)/year],
and subsequently reached a plateau [-0.06 (95% CI: -0.15, 0.55) log10 cpm/year]. The initial
decay was higher in children who achieved VS by 1.5 years of age compared to those who
achieved VS between >1.5 and 4 years and those after 4 years of age: -0.51 (95% CI:-0.94,
-0.07), -0.35 (95% CI:-0.83, 0.14), and -0.21 (95% CI:-0.39, -0.02) log10cpm PBMC/year,
respectively. The 2-LTR circles frequency decayed significantly, from 82.9% at pre-VS to
37.5% and 28.1% at 2 and 4 years of VS, respectively (P = .0009).
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Conclusions
These data highlight that achieving VS during the first 18 months of life limit the establishment of
HIV-1 reservoirs, reinforcing the clinical benefit of very early effective therapy in children.
Introduction
Although antiretroviral therapy (ART) allows sustained viral suppression (VS) in blood
plasma, the ability to eradicate human immunodeficiency virus type 1 (HIV-1) has not been
yet achieved. The principal obstacle to viral eradication is the quick establishment of HIV-1 in
its target cells, mainly in resting memory CD4+ T cells, at the earliest phases of primary infec-
tion [1–3]. The half-life of these resting cells can reach up to several years and contribute to the
persistence of the infection, being recognized as the principal HIV-1 reservoir [4–6].
More than 150,000 new pediatric HIV-1 infections occurred globally during 2015. Mother-to-
child transmission is still the main route of infection in children, despite the extended prophylaxis
regimen: during pregnancy, intrapartum, and the first six weeks after birth [7]. Initially, ART was
recommended only for children with acquired immunodeficiency syndrome-related symptoms
(clinical stage C) or severe immune suppression (stage 3) [8]. However, in recent years, many stud-
ies reported that early initiation of ART in all HIV-1-infected children has clinical benefits [9,10].
Current HIV-1 treatment guidelines strongly recommend ART initiation as soon as possible after
positive HIV-1 diagnosis, regardless of clinical and immunological conditions [11,12]. This coun-
terpart to this scenario is that most HIV-1 infected infants do not have the opportunity to start
ART soon after birth, drugs are inaccessible for many patients, and there are side effects associated
with prolonged ART use [13]. Simplified ART regimens, including break periods or interruption
schedules, are being studied in order to improve treatment adherence and reduce the toxic effects
associated with the drugs [14,15]. These new therapeutic approaches that include HIV-1 infected
patients with low to undetectable plasma viral load (pVL) require ongoing monitoring of the HIV-
1 reservoir size. Estimation of the reservoir size could be important to determine patient response
and avoid the possibility of pVL rebound. An effective biomarker to measure reservoir size and
residual ongoing viral replication has not been established; however, cell-associated HIV-1 DNA
(CA-HIV-DNA) and 2-long terminal repeat (2-LTR) circles levels, respectively, are commonly
used for these purposes [16]. CA-HIV-DNA may remain detectable despite sustained undetectable
pVL; thus, its level of decay might be of interest when assessing the long-term efficacy of ART on
reservoirs. However, it is not well defined how the time to achieve sustained VS, particularly in
those infants who controlled virus replication at chronic stage of infection, impacts on the size of
the HIV-1 reservoir.
The present study was conducted to further understand how the time to achieve effective
ART response affects the persistence of HIV-1 in children throughout successfully suppressed
viremia. The specific aims were to determine the decay of viral reservoirs, estimated by
CA-HIV-DNA and 2-LTR circles, during long-term VS in children initiating ART during
acute and chronic stages of HIV-1 infection, and to assess the impact of the timing to achieve
viral suppression on subsequent CA-HIV-DNA and 2-LTR circles decay.
Materials and methods
Study cohort
The initial cohort included 1,052 HIV-1 infected children who were treated at Hospital de
Pediatrı´a "Prof. Dr. Juan P. Garrahan", a referral pediatric hospital in Buenos Aires, Argentina.
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From this cohort, a subset of 37 patients born between 1990 and 2008 were selected for analysis
based on the following inclusion criteria: I) HIV-1 acquired by vertical transmission; II) VS
present for�4 years; III) first ART regimen based on effective triple therapy, including two
nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) or protease inhibitor (PI); and IV) at least 2 available peripheral blood
mononuclear cell (PBMC) or DNA samples for reservoir size quantification before ART initia-
tion(pre-VS), and during 4 years of VS (Fig 1). Achieving two consecutive pVL below the limit
of quantification (LoQ) of the available assay (range: 37–400 copies/mL) was defined as the
beginning of sustained VS, and also maintaining this level along the study was defined as the
maintenance of VS. Intermittent “blips” in the pVL after achieving VS were allowed, with blips
defined as detectable pVL lower than 1000 copies of HIV-1 RNA/mL in one sample followed
by undetectable levels. Patients were stratified according to the age atART initiation (�0.5 or
>0.5 yrs) and age to achieve VS (�1.5, between>1.5 and 4, and >4 years). The study was
approved by the Institutional Review Board (IRB) and Ethics Committee (EC) of Garrahan
Pediatric Hospital (Protocol number: 856/2015). Written informed consent was obtained from
parents or legal guardians. The consent process was approved by the IRB and EC.
For each patient included in the study, immunological data (CD4+cell, CD8+ T cell, PBMC
and monocyte counts), treatment history, and HIV-1 pVL data were collected.
CA-HIV-DNA quantification and 2-LTR circles detection
Genomic DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
from PBMC following the manufacturer’s protocols. DNA samples were stored at −20˚C until
Fig 1. Study population. Newly HIV-1 infected children detected in Garrahan Pediatric Hospital from 1900 to 2008.
https://doi.org/10.1371/journal.pone.0205579.g001
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use. The quantification of HIV-1 reservoirs, estimated by CA-HIV-DNA, was performed by
semi-nested, real-time polymerase chain reaction (PCR) as previously described [17], with
modification for amplification of ltr-gag region. A combination of previously published [18]
primers-probe sets with newly designed ones based on subtype B, F, and B/F recombinant
strains from the Los Alamos National Laboratory database were used. The LoQ of the assay
was 0.78 log10 copies per one million (cpm) cells. B-globin quantification by real-time PCR
was used to determine the number of PBMC present in each reaction.
Considering that variations of CD4+ T cell counts during HIV-1 infection may induce pro-
found differences in CA-HIV-DNA levels, PBMC and monocyte counts through hemogram
and CD4+ T cells counts by fluorescence-activated cell sorting were used to express
CA-HIV-DNA levels in different units, as previously reported by Avettand-Fènoe¨l et al [19]:
log10 cpm PBMC, log10 cpm CD4
+ T cells, and log10 copies/mL whole blood.
The 2-LTR circle was amplified and detected by hemi-nested real-time PCR using SYBR
Green and a primer set targeting a conserved region of LTR-U5 and LTR-U3. A combination
of previously published [18] primers with newly designed ones were used.
Statistical analysis
The trajectories of CA-HIV-DNA in PBMC, in the proportion of CD4+ T cells, and in whole
blood over 4 years of VS were estimated by a piecewise linear mixed-effects model with a ran-
dom slope for each child. The model included one change of slope at 2 years of VS based on
the minimization of the Akaike information criterion and the immune population changes
over the child’s age. In addition, time at VS and the presence of blips, both expressed as cate-
gorical variables, were included within the model to analyze their impact on CA-HIV-DNA
levels in PBMC over the study period. ART regimen (grouped into NNRTI or PI) at VS and
the basal pVL were tested to estimate the CA-HIV-DNA trajectories; however, they did not
improve the model fit and were therefore not included in the final models. The frequency of
2-LTR circles following VS was studied using a generalized linear model -a logistic regression
for repeated-measures- with the inclusion of CA-HIV-DNA level as a continuous variable.
The Mann-Whitney test and Kruskal-Wallis test were used to compare CA-HIV-DNA lev-
els between two and more than two groups, respectively. Spearman’s correlation coefficient
was used to evaluate the associations between CA-HIV-DNA levels reported in PBMC and
those reported in CD4+ T cells and whole blood.
Statistical analyses were performed with R, version 3.3.1 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Patient characteristics
Baseline characteristics are reported in Table 1. Among the 37 children studied, the median
age at ART was 2.4 [interquartile range (IQR), 0.8–5.1] years. Seven children started ART
before 6 months of infection (IQR, 0.3–0.5 yrs) and 30 children after that time (IQR, 1.8–6.9
yrs). The majority of the children experienced a late effective response to ART, with a median
age to achieve VS of 5.3 (IQR, 3.8–10.8) years. Only 4 (10.8%) children reached VS before 1.5
years, 6 (16.2%) children between>1.5 and 4 years, and 27 (73%) children after 4 years of age.
In addition, 18 (48.6%) children had one or two blips during VS.
Pediatric HIV DNA dynamics over viral suppression
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Cell-associated HIV-1 DNA kinetics
The size of peripheral blood HIV-1 reservoirs was estimated by the level of CA-HIV-DNA.
Among all the patients studied, the CA-HIV-DNA level was below the LoQ at pre-VS in only 5
children; this level persisted over the study period in 3 children, while remaining 2 children
experienced a sustained increment in the CA-HIV-DNA level during VS. ThroughoutVS, 26
(70.3%) patients had quantifiable CA-HIV-DNA levels, and 11 (29.7%) patients had at least
one CA-HIV-DNA measure below LoQ. The rate of decay and predicted mean level of
CA-HIV-DNA estimated in PBMC, CD4+ T cells, and whole blood during VS are detailed in
Table 2 and illustrated in Fig 2. The level of CA-HIV-DNA decayed significantly during the
first two years of VS in all compartments, but it was more pronounced in CD4+ T cells than in
whole blood and in PBMC: -0.41 [95% confidence interval (CI), -0.64 to -0.17] log10cpm
CD4+/year, -0.34 (95% CI, -0.57 to -0.10) log10 copies/mL whole blood/year, and -0.26 (95%
CI, -0.43 to -0.09) log10cpm PBMC/year, respectively. However, the decay rate of
CA-HIV-DNA after 2 years of VS was reduced and was not statistically significant in all
Table 1. Patient characteristics.
Characteristic Value
Subjects, No. 37
Sex, No. (%), Female 19 (51.4)
ACTG 076 prophylaxis regimen, No. (%)a
- None 24 (64.9)
- Partial 5 (13.5)
- Complete 5 (13.5)
- Unknown 3 (8.1)
Age at ART initiation, median (IQR), yrs 2.4 (0.8–5.1)
First ART regimen, No. (%)
- 2 NRTIs + NNRTI 16 (43.2)
- 2 NRTIs + PI 21 (56.8)
Age at VS, median (IQR), yrs 5.3 (3.8–10.8)
ART regimen at VS, No. (%)
- 2 NRTIs + NNRTI 23 (62.2)
- 2 NRTIs + PI 14 (37.8)
Time from ART initiation to VS, median (IQR), yrs 2.1 (0.5–4.1)
pVL at pre-VS, median (IQR), log10 copies/mL 5.89 (5.03–6.25)
Immunologic population at pre-VS
- CD4+ T cell counts, median (IQR), % 19 (13–27)
- CD4+ T cell counts, median (IQR), cells/mm3 788 (325–1494)
- CD4:CD8 ratio, median (IQR) 0.49 (0.39–0.67)
Immunologic population at end point
- CD4+ T cell count, median (IQR), % 34 (30–39)
- CD4+ T cell count, median (IQR), cells/mm3 956 (691–1130)
- CD4:CD8 ratio, median (IQR) 1.00 (0.78–1.29)
a Classification criteria based on ACTG 076: Complete, zidovudine administration to HIV-1 infected women during
pregnancy and to the child during the first six weeks of life; Partial, zidovudine administration only to the HIV-
1-infected pregnant woman or to the child; None, no zidovudine administration.
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; NNRTIs, non-nucleoside reverse transcriptase
inhibitors; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; pVL, plasma viral load; VS, viral
suppression.
https://doi.org/10.1371/journal.pone.0205579.t001
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compartments: -0.08 (95% CI, -0.14 to 0.80) log10cpm CD4
+/year, -0.08 (95% CI, -0.79 to 0.63)
log10 copies/mL whole blood/year, and -0.06 (95% CI, -0.15 to 0.55) log10cpm PBMC/year.
The predicted mean level of CA-HIV-DNA in PBMC was 2.55 [95% prediction interval
(PI), 2.18 to 2.93] log10cpm PBMC at VS and decayed to 2.03 (95% PI, 1.79 to 2.27) and 1.98
(95% PI, 1.66 to 2.30) log10cpm PBMC at 2 and 4 years of VS, respectively. These levels were
lower than those expressed in the proportion of CD4+ T cells and whole blood. However,
CA-HIV-DNA levels in PBMC were highly correlated with those levels in CD4+ T cells
(r = 0.97, P < .0001) and in whole blood (r = 0.98, P< .0001).
Moreover, we observed a similar rate of decay in CA-HIV-DNA in PBMC between 2 and 4
years of VS in children who experienced the emergence of blips in comparison with those
without blips: -0.02 (95% CI, -0.57 to 0.53) and -0.10 (95% CI, -0.63 to –0.44) log10cpm
PBMC/year, respectively (P = .5702).
We further examined the effect of the age of infection at ART initiation on the level of
CA-HIV-DNA in PBMC at 2 and 4 years of VS. The median level of CA-HIV-DNA in infants
who started ART before 6 months of infection was 1.96 (IQR, 1.66–2.17) and 1.90 (IQR, 1.15–
2.23) log10cpm PBMC at 2 and 4 years of VS, respectively, while infants who initiated ART
afterward had a median level of 1.96 (IQR, 1.30–2.78) and 1.91 (IQR, 0.90–2.48) log10cpm
PBMC at 2 and 4 years of VS, respectively. No significant difference was observed in the level
of CA-HIV-DNA according to the time at ART initiation at 2 and 4 years of VS (P = .7632 and
P = .5701, respectively).
Finally, we analyzed the decay rates of CA-HIV-DNA according to the age of infection at
VS (�1.5, >1.5–4, and>4 years). These results are shown in Table 3 and Fig 3. Slopes from
children who achieved VS by 1.5 years of ageand from those who achieved VS after 4 years of
Table 2. Estimated decay rates and predicted means of cell-associated HIV-1 DNA level over 4 years of sustained viral suppression and expressed in different units.
Variable PBMCs CD4+cells Whole Blood
No. of measurements 98 92 93
Intercepta
- Estimated (95% CI) 2.44 (2.17 to 2.70) 3.15 (2.79 to 3.50) 3.01 (2.66 to 3.35)
First slope (0–2 yrs)b
- Estimated (95% CI) -0.26 (-0.43 to -0.09) -0.41 (-0.64 to -0.17) -0.34 (-0.57 to -0.10)
- P-valuec .0028 .0009 .0056
Second slope (2–4 yrs)b
- Estimated (95% CI) -0.06 (-0.15 to 0.55) -0.08 (-0.14 to 0.80) -0.08 (-0.79 to 0.63)
- P-valuec .2578 .1619 .2842
Level of CA-HIV-DNAd
- At 0 yrs of VS, mean (95% PI) 2.55 (2.18 to 2.93) 3.35 (2.82 to 3.88) 3.16 (2.64 to 3.68)
- At 2 yrs of VS, mean (95% PI) 2.03 (1.79 to 2.27) 2.53 (2.23 to 2.84) 2.49 (2.20 to 2.78)
- At 4 yrs of VS, mean (95% PI) 1.98 (1.66 to 2.30) 2.38 (1.96 to 2.81) 2.38 (1.97 to 2.80)
aThe intercept represents the estimated basal level of CA-HIV-DNA and is expressed in different units by column: log10 cpm PBMC, log10 cpm CD4
+ T-cells and log10
copies/mL whole blood.
bSlopes represent the decay rate of CA-HIV-DNA at different ages of VS and are expressed in different units by column: log10 cpm PBMC/year, log10 cpm CD4
+ T-cells/
year, and log10 copies/mL whole blood/year.
cP-value represents the statistical significance of each decay rate in each compartment estimated by piecewise linear mixed-effects model.
dLevels are expressed in different units by column: log10 cpm PBMC, log10 cpm CD4
+ T-cells and log10 copies/mL whole blood. The 95% PIs were predicted from the
final model.
Abbreviations: CA-HIV-DNA, cell-associated HIV-1 DNA; CI, confidence interval; PBMC, peripheral blood mononuclear cell; PI, prediction interval; VS, viral
suppression.
https://doi.org/10.1371/journal.pone.0205579.t002
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age were significantly negative (P = .0235, P = .0287, respectively) during the first 2 years of
VS. At that time, a higher decay rate of CA-HIV-DNA was observed in children who achieved
VS by 1.5 years of age in comparison to those who achieved VS between>1.5 and 4 years and
after 4 years of age: -0.51 (95% CI, -0.94 to -0.07), -0.35 (95% CI, -0.83 to 0.14), and -0.21 (95%
CI, -0.39 to -0.02) log10cpm PBMC/year, respectively. However, the overall difference among
these slopes was not statistically significant (P = .1645). After 2 years of VS, CA-HIV-DNA
decay rate (second slope) was very slow and similar among all groups, with no statistically sig-
nificant value in any group (P = .7346). Furthermore, the predicted mean level of
CA-HIV-DNA after 4 years of VS tended to be lower in children who achieved VS before 1.5
years of age compared to those with VS between>1.5 and 4 years and those after 4 years of
age: 1.56 (95% PI, 0.75 to 2.37), 1.83 (95% PI, 0.94 to 2.73), and 2.08 (95% PI, 1.73 to 2.43)
log10cpm PBMC, respectively (P = .1942).
Detection of 2-LTR circles and its association with CA-HIV-DNA levels
Among the 37 patients included in the study, the presence of 2-LTR circles was determined in
35 patients at pre-VS, in 24 patients at 2 years of VS, and in 32 patients at 4 years of VS. The
frequency of children with detectable 2-LTR circles decayed over VS, from 82.9% (29/35) at
pre-VS to 37.5% (9/24) and 28.1% (9/32) at 2 and 4 years of VS, respectively. The logistic
regression analysis for repeated measures showed a significant decay in the frequency of
Fig 2. Decay rates of CA-HIV-DNA from children with sustained viral suppression according to the
compartment analyzed. Individual lines indicate the trajectories of CA-HIV-DNA based on the model prediction.
Individual points represent the quantification of HIV-1 DNA from each patient at specific time points. Levels of
CA-HIV-DNA expressed as log10 cpm PBMC for PBMC, log10 cpm CD4
+ T cells for CD4+ T-cells, and log10 copies/
mL whole blood for whole blood.
https://doi.org/10.1371/journal.pone.0205579.g002
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2-LTR circles detection during VS (P = .0009). No significant difference in 2-LTR circles detec-
tion at 4 years of VS was observed among the children grouped according to the age at VS (1/3
patients 1.5 years or earlier, 1/4 between >1.5 and 4 years and 7/25 after 4 years of age). Fur-
thermore, children with detectable 2-LTR circles showed a higher median level of
CA-HIV-DNA compared to those with undetectable 2-LTR circles [2.48 (IQR, 1.68–3.01) vs.
1.89 (IQR, 0.78–2.39) log10cpm, P < .005].
Discussion
In this study, we evaluated the evolution of HIV-1 reservoir size on PBMC in vertically HIV-
1-infected children. Our results showed a marked decay of HIV-1 DNA reservoir size during
the first two years of VS, being higher in those children with earlier age at VS. Then, this decay
reaches a plateau independently of the age at viral suppression.
Reduced size of HIV-1 reservoirs has been reported in adults and children who started
ART at early stage of infection. However, there are controversial results regarding what time is
early enough to limit reservoir size and also it depends on which cell subset is studied [20–23].
The kinetics of HIV-1 reservoirs has been well reported in adults, but there are few studies in
children, mainly analyzing the immediate effect after ART initiation and with short follow-up
[24]. Notwithstanding, the kinetics of HIV-1 reservoirs in pediatric population over a long
term of VS and how they are affected by the age at VS are poorly defined. In this study, we
address these issues by studying longitudinally children who achieved effective response to
ART at different times. It is important to mention, that due to the retrospectively design of the
study and the availability of store PBMCs samples, most of the children started ART later and
some who started early had a delay to achieve viral suppression. Nowadays, following interna-
tional guidelines HIV infected children start ART soon after diagnosis (mainly during the first
Table 3. Estimated decay rates and predicted means of cell-associated HIV-1 DNA level in PBMC over 4 years of sustained viral suppression according to theage at
viral control.
Age at VS
Variable �1.5 yrs >1.5–4 yrs >4 yrs P-valued
No. of children 4 6 27 NA
Intercepta
- Estimated (95% CI) 2.44 (2.18 to 2.70) 2.44 (2.18 to 2.70) 2.44 (2.18 to2.70) NA
First slope (0–2 yrs)b
- Estimated (95% CI) -0.51 (-0.94 to -0.07) -0.35 (-0.83 to 0.14) -0.21 (-0.39 to -0.02) .1645
- P-valuec .0235 .1583 .0287
Second slope (2–4 yrs)b
- Estimated (95% CI) -0.001 (-1.50 to 1.50) -0.11 (-1.64 to 1.44) -0.07 (-0.63 to 0.49) .7346
- P-valuec .3477 .6495 .4798
Level of CA-HIV-DNA (log10 cpm PBMC)
- At 0 yrs of VS, mean (95% PI) 2.73 (2.01 to 3.45) 2.58 (1.86 to 3.30) 2.52 (2.13 to 2.90) .5941
- At 2 yrs of VS, mean (95% PI) 1.72 (1.24 to 2.20) 1.89 (1.40 to 2.37) 2.11 (1.85 to 2.37) .1614
- At 4 yrs of VS, mean (95% PI) 1.56 (0.75 to 2.37) 1.83 (0.94 to 2.73) 2.08(1.73 to 2.43) .1942
aThe intercept represents the estimated basal level of CA-HIV-DNA and is expressed in log10 cpm PBMC.
bSlopes represent the decay rate of CA-HIV-DNA at different ages of VS for each group and they are expressed in log10 cpm PBMC/year.
cP-value represents the statistical significance of each decay rate in each group estimated by piecewise linear mixed-effects model.
dP-value represents the statistical significance of the comparison among children with age at VS of�1.5, >1.5–4, and >4 years.
Abbreviations: CA-HIV-DNA, cell-associated HIV-1 DNA; CI, confidence interval; PBMC, peripheral blood mononuclear cell; PI, prediction interval; NA, not
applicable; VS, viral suppression.
https://doi.org/10.1371/journal.pone.0205579.t003
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year of life). However, in resource-limiting countries a delay in pediatric HIV diagnosis is still
frequent with the consequently late initiation of therapy. Hence, exploring the dynamics of the
viral reservoirs in these populations might bring insights of their behavior in well-established
infection in children. Moreover, these patients might serve as good control groups for studies
comparing the kinetics of viral reservoirs in children who start ART at early or very early steps
of infection.
Our results showed a significant decay rate of CA-HIV-DNA level over the first two years
of sustained VS. This was in concordance with previous studies performed in adults by Laa-
nani et al [20] and Besson et al [25]. However, after 2 years of VS, the level of CA-HIV-DNA
remained almost in a steady state. This plateau phase of CA-HIV-DNA might reflect ongoing
viral replication or viral release from stable reservoirs [26–28]. Additionally, survival of long-
lived HIV-1 infected cells could be another key factor contributing to the stability of the reser-
voir size, but their persistence during 4 years of VS is unlikely.
Activation of target cells and latently infected cells by concurrent infection or immune sup-
pression by opportunistic infections might contribute to ongoing viral replication [29]. In our
cohort, children with and without blips (48.6% vs 51.4%) had no difference in the decay rate of
CA-HIV-DNA over VS, suggesting that a transitory viral rebound seems not to be enough to
modify the whole size of HIV-1 reservoirs. In contrast, Ramratnam et al [30] observed that the
rate of decay of HIV-1 reservoir is inversely correlated with the extent of residual viral replica-
tion during ART. Whether the time elapsed to recover VS since viral rebound occurred or if
the highest level of viremia at rebound could modify reservoir size need to be addressed.
Fig 3. Decay rates of CA-HIV-DNA from children with sustained viral suppression according to the age of
infection at VS. Individual lines indicate the trajectories of CA-HIV-DNA based on the model prediction. Individual
points represent the quantification of HIV-1 DNA from each patient at specific time points.
https://doi.org/10.1371/journal.pone.0205579.g003
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It is accepted that the earlier ART is initiated, the smaller the size of the HIV-1 reservoir
[24].However, we did not observedifferences in the CA-HIV-DNA level after 4 years of VS
between children starting ART before (n = 7) and after (n = 30) six months of age. This could
be explained in part by the unbalanced number of children in both groups and also by a late
effective viral control observed in our cohort despite early ART initiation. Furthermore, a
recent study showed an absence of significant difference in CA-HIV-DNA levels during 96
weeks of ART among children who started ART before and after 6 weeks of life [31]. These
findings suggest that the establishment of HIV-1 reservoirs occur very early—probably during
the first hours after infection, that could be in utero as the Mississippi child [32].
We further analyzed whether there was an association between the age at VS and the decay
rate of CA-HIV-DNA during VS. We found that the decay rate of CA-HIV-DNA during the
first two years of VS tended to be higher in children who reached effective viral control by 1.5
years of age than in those beyond 1.5 years. Additionally, the predicted level of CA-HIV-DNA
at 4 years of VS was lower when the time at VS was�1.5 years of age. In line with our findings,
Persaud and colleagues reported, in a cross-sectional study, a significant difference in
CA-HIV-DNA levels after 7.2 years of VS among children who suppressed plasma viremia
before 1 year and after 5 years of age [33]. However, the authors did not find a significant dif-
ference between the groups who achieved VS before 1 year compared to 1–5 years or between
the latter group and those after 5 years of age.
There are many controversies regarding data concerning the stability of 2-LTR circles and,
in consequence, its value as a surrogate marker for ongoing replication. Some studies reported
that 2-LTR circles are labile forms and thus their presence is indicative of recent infection
events [34,35]. However, other studies indicated that these episomal HIV-1 forms are intrinsi-
cally stable in vitro [36,37]. In the present study, we found that, at ART initiation, even with
high pVL (approximately 5 log10 copies/mL), 80% of the children had detectable levels of
2-LTR circles. This could reflect a methodological limitation since we isolated total DNA from
PBMC instead of episomal DNA, which seems to improve 2-LTR circles detection [38]. Similar
to the frequency observed with CA-HIV-DNA, the frequency of children with detectable
2-LTR circles significantly decreased over VS, and it was higher (28%) than it was reported by
Koelsch et al [39] even at 4 years of VS. This level could be even higher taking into account the
methodological limitation discussed above. Two main hypotheses might explain this: (1) ongo-
ing viral replication during VS manifested by residual viremia allows de novo generation of
HIV-1 episomal forms or (2) 2-LTR circles generated before suppressive ART persists for lon-
ger time than expected, remaining detectable even during many years of sustained VS in
children.
Some limitations of the present study include the predominance of children with late effec-
tive response to ART, resulting in some groups analyzed being imbalanced; therefore, the
decay of HIV-1 reservoirs in those groups might be underpowered. Also, the subjective data
on ART adherence in our pediatric cohort could underestimate the impact of time at ART ini-
tiation on HIV-1 reservoirs.On the other hand, it is important to highlight that molecular
DNA assays could overestimates the size of the reservoirs since they detect intact and defective
viruses [16,40]
The high level and the low decay rate of CA-HIV-DNA during VS found in our study seem
to be an obstacle for ART-free remission. However, it has been previously reported that more
than 95% of CA-HIV-DNA is defective to produce replication-competent viruses [41,42]. In
this sense, the adults ANRS VISCONTI cohort study [43] and, more recently, the French
ANRS EPF-CO10 pediatric cohort [44] demonstrated that functional cure could be achieved
without complete elimination of CA-HIV-DNA. In a recent, very novel study, Imamichi and
colleagues [41] proposed that defective proviruses are capable of transcribing unspliced HIV-1
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RNA producing intact HIV-related proteins in patients receiving ART who suppressed pVL
for many years. Collectively, these findings lead to a new understanding of the role of
CA-HIV-DNA in HIV-1 cure studies.
In conclusion, our data highlight the difficulty to eliminate the circulating reservoirs from
peripheral blood. Also, our results support that the age to reach VS may be a better predictor
of the size of HIV-1 reservoirs on PBMC in children after a prolonged time of VS than the age
at ART initiation, reinforcing the clinical benefit of very early effective therapy.
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